Fusions of NTRK1, NTRK2, and NTRK3 genes are rare alterations in CCA (0.7–1.8% of cases).232,233 Two basket trials investigated larotrectinib and entrectinib in TRK-fusion-positive cancers involving three patients with CCA. This evidence concerns the gene NTRK1 and cancer.